Education
About Us
Working with TipRanks
Follow Us
Ocular Therapeutix Inc (OCUL)
:OCUL
OCUL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.79 - $13.85
Previous CloseN/A
Volume219.73K
Average Volume (3M)3.04M
Market Cap
$2.32B
Enterprise Value$1.29B
Total Cash (Recent Filing)$391.13M
Total Debt (Recent Filing)$76.94M
Price to Earnings (P/E)―
Beta1.94
Next Earnings
Nov 10, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding211,904,240
10 Day Avg. Volume4,313,919
30 Day Avg. Volume3,043,791
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.55
Enterprise Value/Revenue22.75
Enterprise Value/Gross Profit25.44
Enterprise Value/Ebitda-6.30
Forecast
1Y Price Target
$20.50Price Target Upside77.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Bulls Say, Bears Say
Bulls Say
Clinical StrategyOCUL announced its diabetic retinopathy clinical strategy and approach to wAMD clinical adoption during its Investor Day, which is seen as a positive development.
Market OpportunityThere is a large potential opportunity in treating the ~6.5 million US NPDR patients, as less than 1% currently receive therapy.
Regulatory PathFDA alignment under SPA for registrational trial in NPDR provides a clear regulatory path forward.
Bears Say
Market CompetitionAxpaxli has the potential to significantly improve outcomes in this population with only one or two injections per year, which would alleviate the treatment burden of current anti-VEGF therapies, but it faces competition from established treatments.
Regulatory ChallengesThe comprehensive Phase III HEALIOS program in NPDR is employing a novel ordinal DRSS endpoint and trial designs, which could present challenges in pursuing a broad superiority label in DR.
Ocular Therapeutix News
OCUL FAQ
What was Ocular Therapeutix Inc’s price range in the past 12 months?
Ocular Therapeutix Inc lowest stock price was $5.79 and its highest was $13.85 in the past 12 months.
What is Ocular Therapeutix Inc’s market cap?
Ocular Therapeutix Inc’s market cap is $2.32B.
When is Ocular Therapeutix Inc’s upcoming earnings report date?
Ocular Therapeutix Inc’s upcoming earnings report date is Nov 10, 2025 which is in 32 days.
How were Ocular Therapeutix Inc’s earnings last quarter?
Ocular Therapeutix Inc released its earnings results on Aug 05, 2025. The company reported -$0.39 earnings per share for the quarter, missing the consensus estimate of -$0.357 by -$0.033.
Is Ocular Therapeutix Inc overvalued?
According to Wall Street analysts Ocular Therapeutix Inc’s price is currently Undervalued.
Does Ocular Therapeutix Inc pay dividends?
Ocular Therapeutix Inc does not currently pay dividends.
What is Ocular Therapeutix Inc’s EPS estimate?
Ocular Therapeutix Inc’s EPS estimate is -0.37.
How many shares outstanding does Ocular Therapeutix Inc have?
Ocular Therapeutix Inc has 211,904,240 shares outstanding.
What happened to Ocular Therapeutix Inc’s price movement after its last earnings report?
Ocular Therapeutix Inc reported an EPS of -$0.39 in its last earnings report, missing expectations of -$0.357. Following the earnings report the stock price went down -2.834%.
Which hedge fund is a major shareholder of Ocular Therapeutix Inc?
Currently, no hedge funds are holding shares in OCUL
Ocular Therapeutix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.50 (77.95% Upside)
$20.50 (77.95% Upside)
Blogger Sentiment
Bullish
OCUL Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 982.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $577.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.6%
Last 30 Days ▲ 10.9%
Last 30 Days ▲ 10.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.51%
12-Months-Change
Fundamentals
Return on Equity
-63.41%
Trailing 12-Months
Asset Growth
-12.72%
Trailing 12-Months
Company Description
Ocular Therapeutix Inc
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for diseases and conditions of the eye. The company specializes in creating sustained-release drug products using its proprietary hydrogel platform technology, which allows for extended delivery of medications to the ocular surface. Ocular Therapeutix's core products include Dextenza, a drug-eluting implant for the treatment of post-surgical pain and inflammation, and OTX-TP, an investigational product for the treatment of glaucoma and ocular hypertension.
OCUL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted significant advancements in clinical trials and a strong financial position, indicating optimism about the future potential of AXPAXLI. The challenges mentioned, such as adjustments in rescue criteria, were addressed strategically, reflecting confidence in the drug's profile.View all OCUL earnings summariesOCUL Stock 12 Month Forecast
Average Price Target
$20.50
▲(77.95% Upside)
Technical Analysis
89bio
―
Beam Therapeutics
―
Tarsus Pharmaceuticals
―
ARS Pharmaceuticals
―
Belite Bio, Inc. ADR
―
Ownership Overview
3.07% Insiders
11.27% Mutual Funds
46.81% Other Institutional Investors
29.16% Public Companies and
Individual Investors